Page last updated: 2024-11-08

rimiterol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

rimiterol: was heading 1977-94 (see under CATECHOLS 1977-90); use CATECHOLS to search RIMITEROL 1977-94; predominantly a beta 2 stimulant, therefore affects the cardiovascular system less than isoproterenol, but its action is of shorter duration than that of albuterol [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID431097
CHEMBL ID88055
CHEBI ID134917
SCHEMBL ID3130599
MeSH IDM0224688

Synonyms (12)

Synonym
CHEMBL88055
NCI60_002370
4-(hydroxy(2-piperidinyl)methyl)-1,2-benzenediol
rimiterol
CHEBI:134917
4-[hydroxy(piperidin-2-yl)methyl]benzene-1,2-diol
rimiterolum
32953-89-2
SCHEMBL3130599
(3,4-dihydroxyphenyl)(piperid-2-yl)methanol
erythro-3,4-dihydroxyphenyl-2-piperidylcarbinol
DTXSID00865656

Research Excerpts

Overview

Rimiterol is an effective, short-acting bronchodilator, with similar beta2-selectivity to salbutamol, when administered intravenously to asthmatic patients. Rimiterol lacks the cardiovascular effects of isoprenaline.

ExcerptReferenceRelevance
"3 Rimiterol is a selective, short-acting, sympathomimetic bronchodilator in children."( The acute effects of the administration of rimiterol aerosol in asthmatic children.
Blackhall, MI; Macartney, B; O'Donnell, SR, 1978
)
1.08
"Rimiterol is an effective, short-acting bronchodilator, with similar beta2-selectivity to salbutamol, when administered intravenously to asthmatic patients."( The relative potencies and beta2-selectivities of intravenous rimiterol, salbutamol and isoprenaline in asthmatic patients.
Marlin, GE; Turner, P, 1975
)
1.22
"Rimiterol is an acceptable alternative to the short-acting isoprenaline but lacks the cardiovascular effects of isoprenaline and is an alternative to salbutamol where very prolonged action is unnecessary."( Comparison between the bronchodilator and cardiovascular effects of inhaling 0.5 mg. rimiterol ('Pulmadil') and 0.2 mg. salbutamol.
Bianco, S; Kamburoff, PL; Prime, FJ, 1975
)
1.2

Actions

ExcerptReferenceRelevance
"5. Rimiterol, because it does not produce direct coronary vasodilation may be preferable to isoprenaline in the treatment of low-cardiac output syndrome where there is regional myocardial ischaemia, since it would be less likely to produce a "coronary steal" effect."( Comparative peripheral and coronary haemodynamic effects of rimiterol and isoprenaline.
Adams, L; Ead, H; Hayward, RP; Spurrell, RA; Stephens, JD, 1978
)
1.01

Bioavailability

ExcerptReferenceRelevance
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31

Dosage Studied

ExcerptRelevanceReference
" In this dosage it was found that the peak effect of the two drugs was the same but that the effect of rimiterol was less prolonged than that of sulbutamol."( Comparison between the bronchodilator and cardiovascular effects of inhaling 0.5 mg. rimiterol ('Pulmadil') and 0.2 mg. salbutamol.
Bianco, S; Kamburoff, PL; Prime, FJ, 1975
)
0.69
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
catecholsAny compound containing an o-diphenol component.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID22293Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-199029 (87.88)18.7374
1990's0 (0.00)18.2507
2000's1 (3.03)29.6817
2010's2 (6.06)24.3611
2020's1 (3.03)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.02 (24.57)
Research Supply Index4.01 (2.92)
Research Growth Index4.67 (4.65)
Search Engine Demand Index36.71 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials20 (58.82%)5.53%
Reviews2 (5.88%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (35.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]